Supplementary data for:

SGLT2 inhibitors activate pantothenate kinase in the human heart

Nicholas Forelli[1], Deborah Eaton[1], Jiten Patel[1], Caitlyn E. Bowman[1], Ryo Kawakami[1], Ivan A. Kuznetsov[1], Kristina Li[1], Claire Brady[1], Kenneth Bedi[1], Yijun Yang[1], Kaustubh Koya[1], Emily Megill[2], Daniel S. Kanter[2], Louis Smith[3], Gregory R. Bowman[3], Nathaniel Snyder[2], Jonathan Edwards[4], Kenneth Margulies[1], Zoltan Arany[1]

[1]Cardiovascular Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
[2]Aging & Cardiovascular Discovery Center, Department of Cardiovascular Sciences, Lewis Katz School of Medicine at Temple University, Philadelphia, PA
[3]Departments of Biochemistry & Biophysics and Bioengineering, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
[4]Division of Cardiology, Children's Hospital of Philadelphia, Philadelphia, PA


Correspondence:

Zoltan Arany, MD PhD
TRC 11-106
Perelman School of Medicine
Philadelphia, PA, 19104
zarany@pennmedicine.upenn.edu

Supplementary Table

Human Patient Characteristics

| Sample	Etiology	Sex	Age	LV Mass Index	BMI	LVEF	Experiment
1	NICM	M	49	125.74	23.03	17.5	Figure 1
2	HCM	M	31	116.82	30.46	15	Figure 1
3	ICM	F	44	207.32	31.96	30	Figure 1
4	NICM	M	52	150.38	32.82	15	Figure 1
5	NICM	F	46	97.98	22.03	10	Figure 1
6	NICM	F	26	77.66	22.58	15	Figure 1
7	Sarcoid	M	61	125	29.06	20	Figure 1, Figure 2b
8	NICM	F	68	122.23	24.44	27.5	Figure 1
9	HFpEF	M	62	106.48	25.14	57.5	Figure 1
10	ARCV	F	61	127.99	24.09	70	Figure 1
11	NICM	M	59	147.97	32.77	10	Figure 1, Figure 2b
12	HFpEF	M	61	133.18	34.34	55	Figure 2b
13	HFpEF	M	58	117.79	22.40	55	Figure 2b
14	Sarcoid	M	59	139.33	37.22	30	Figure 2b
15	Congenital	F	7		19.13		Figure 2b
16	NF	F	56	111.38	25.22	55	Figure 2c
17	NF	F	56	98.39	20.70	70	Figure 2c
18	NF	F	69	139.48	33.50	52.5	Figure 2c
19	NF	F	61	116.12	30.43	57	Figure 2c
20	NF	F	54	114.71	36.11	55	Figure 2c
21	NF	M	62	1411.62	23.66	65	Figure 2c
22	NF	M	58	77.33	23.66	65	Figure 2c
23	NF	M	20	141.62	23.66	65	Figure 2c
24	NICM	F	46	97.98	24.03	10	Figure 2c
25	NICM	M	28	169	30.52	12	Figure 2c
26	Sarcoid	M	61	125	29.06	20	Figure 2c
27	NICM	M	49	125.74	23.03	17.5	Figure 2c
28	HCM	M	59	116.82	30.48	15	Figure 2c
29	NICM	F	26	77.66	22.58	15	Figure 2c
30	NICM	M	59	147.92	32.77	10	Figure 2c
31	NICM	F	68	12.23	24.44	27.5	Figure 2c
32	NICM	M	52	150.35	32.82	15	Figure 2c
33	ICM	F	53	106.59	28.52	59	Figure 2c
34	Sarcoid	M	59	139.33	37.22	30	Figure 2c

Supplementary Figures

Supplementary figure 1. **A,** CETSA of PANK1 from HepG2 cells treated with 10uM Empagliflozin. **B,** CETSA of PANK1 from HEK293 cells treated with vehicle (0.01% DMSO), 10uM Empagliflozin, or 10uM PZ-2891.

Supplementary Figure 2. Single-point enzyme activity assays of PANK1 utilizing 2 different kinase activity assays with 1uM of EMPA *in vitro*. Left: Transcreener ADP Assay (Bellbrook labs) Kit single point kinase activity assay.[1] Right: Malachite green-coupled ADP detection single point kinase activity assay.

Supplementary Figure 3. Additional contractility parameters, accompanying Figure 4.